| Q37650212 | A review of rodent models of type 2 diabetic skeletal fragility |
| Q50877793 | Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells. |
| Q47291173 | Antagonists of Wnt/β-catenin signalling in the periodontitis associated with type 2 diabetes and smoking |
| Q26750574 | Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions |
| Q41294180 | Bone cells and bone turnover in diabetes mellitus |
| Q91671984 | Clinical aspects and management of osteoporosis and fragility fractures in patients with diabetes |
| Q51707392 | Decreased Plasma Levels of Sclerostin But Not Dickkopf-1 are Associated with an Increased Prevalence of Osteoporotic Fracture and Lower Bone Mineral Density in Postmenopausal Korean Women. |
| Q64936056 | Diabetes Mellitus-induced Bone Fragility. |
| Q90678486 | Diagnosis and management of bone fragility in diabetes: an emerging challenge |
| Q42377473 | Fenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model. |
| Q47255490 | Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial |
| Q30241947 | Mechanisms of diabetes mellitus-induced bone fragility |
| Q38846381 | Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy |
| Q90123832 | Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus |
| Q47621636 | Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients |
| Q38359423 | Sclerostin and CKD-MBD. |
| Q89967626 | Sclerostin and Its Associations With Bone Metabolism Markers and Sex Hormones in Healthy Community-Dwelling Elderly Individuals and Adolescents |
| Q40815830 | Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density. |
| Q38569480 | Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder. |
| Q89868512 | Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes |
| Q58725004 | Skeletal Fragility in Type 2 Diabetes Mellitus |
| Q50021725 | Skeletal fragility in diabetes |
| Q38921875 | The Utility of Biomarkers in Osteoporosis Management. |
| Q27012497 | The alliance of mesenchymal stem cells, bone, and diabetes |
| Q92966156 | The role of osteoblasts in energy homeostasis |
| Q39060946 | Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures |